Wir sind mit live! Mehr erfahren

Perrigo

PRGO

Börsenwert 2,31 Mrd. $

16,63 USD

+0,15

0,91 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

16,63

0,00

0 %

1 Tag

0,91 %

5 Tage

11,61 %

1 Monat

22,82 %

3 Monate

49,01 %

6 Monate

45,62 %

Seit Jahresbeginn

19,73 %

1 Jahr

-22,76 %

5 Jahre

-62,85 %

10 Jahre

-80,76 %

Profil: Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Mitarbeiter: 8.100

Gesundheitswesen Arzneimittelhersteller – Spezialpräparate und Generika

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 68,4 %

Neutral 31,6 %

Negativ 0 %

Zacks Investment Research

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Zacks Investment Research

Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?

Perrigo to Attend the Barclays Global Consumer Conference

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo   Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.

Perrigo to Attend the Barclays Global Consumer Conference

Zacks Investment Research

PRGO or NEOG: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

PRGO or NEOG: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Should Value Investors Buy Perrigo (PRGO) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Perrigo (PRGO) Stock?

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

My Top 5 Dividend Picks For August

I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.

My Top 5 Dividend Picks For August

Perrigo: The Rebound Is Just Getting Started

Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

Perrigo: The Rebound Is Just Getting Started

Zacks Investment Research

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Zacks Investment Research

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt